Chronic Obstructive Pulmonary Disease
Conditions
Keywords
chronic obstructive pulmonary disease,, COPD,, Oxis,
Brief summary
The purpose of the investigation is to confirm the ADR development and the contributing factors possibly having an impact on the safety under the post-marketing actual use of Oxis 9 mcg Turbuhaler.
Detailed description
Oxis 9mcg Turbuhaler Clinical Experience Investigation
Interventions
None listed
Sponsors
AstraZeneca
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
\- Patients treated with Oxis for the first time due to 'relief of various symptoms associated with airway obstructive disorders of chronic obstructive pulmonary disease (Chronic bronchitis, Pulmonary emphysema), which is the indication of this drug.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse event incidence | 12 weeks |
Countries
Japan
Outcome results
None listed